Brown Brothers Harriman & Co. Takes Position in Certara, Inc. (NASDAQ:CERT)

Brown Brothers Harriman & Co. bought a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,330,615 shares of the company's stock, valued at approximately $27,292,000. Brown Brothers Harriman & Co. owned about 1.45% of Certara as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of CERT. Blue Trust Inc. purchased a new stake in Certara during the second quarter valued at about $26,000. Innealta Capital LLC purchased a new position in Certara in the second quarter valued at approximately $36,000. KBC Group NV lifted its position in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after buying an additional 1,584 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Certara during the second quarter worth approximately $152,000. Finally, Algert Global LLC purchased a new position in shares of Certara in the 2nd quarter valued at $156,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Performance

NASDAQ:CERT traded up $0.69 during trading hours on Monday, reaching $11.05. 1,456,925 shares of the stock were exchanged, compared to its average volume of 801,487. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.78 billion, a P/E ratio of -56.30, a P/E/G ratio of 5.24 and a beta of 1.51. The firm has a 50 day simple moving average of $10.79 and a 200-day simple moving average of $13.17.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company had revenue of $94.80 million for the quarter, compared to analysts' expectations of $95.51 million. During the same period in the prior year, the company earned $0.06 earnings per share. The firm's revenue was up 10.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The trade was a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the company's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares of the company's stock, valued at approximately $552,503.73. This represents a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on CERT. Barclays cut their price objective on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Thursday, November 7th. UBS Group raised shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a research report on Friday, September 27th. Finally, Robert W. Baird dropped their price target on shares of Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.